Simultaneous administration of imipenem/cilastatin/relebactam with selected intravenous antimicrobials, a stewardship

Islam M Ghazi1, Wasim S El Nekidy2, Regan Asay1

  • 1Philadelphia College of Pharmacy, University of the Sciences, Philadelphia, PA, United States of America.

Plos One
|May 19, 2020
PubMed

Insights

Imipenem/cilastatin/relebactam (Recarbrio®) is compatible with most antimicrobials for Y-site administration, simplifying treatment for severe infections. This compatibility study supports optimized drug administration, reducing infusion times and healthcare costs.

Area of Science:

  • Pharmacology
  • Infectious Diseases
  • Clinical Pharmacy

Background:

  • Imipenem/cilastatin/relebactam (Recarbrio®) is FDA-approved for complicated infections.
  • It targets resistant bacteria like imipenem-non-susceptible Pseudomonas and KPC-producing Enterobacteriaceae.
  • Optimizing antimicrobial pharmacokinetics/pharmacodynamics (PK/PD) in critically ill patients is crucial but challenging due to separate administration needs.

Purpose of the Study:

  • To assess the Y-site administration compatibility of imipenem/cilastatin/relebactam with various antimicrobial agents.
  • To provide data supporting the co-administration of imipenem/cilastatin/relebactam with other antimicrobials.

Main Methods:

  • Physical characteristics, pH, and turbidity were measured for 2-drug admixtures.
  • Imipenem/cilastatin/relebactam was combined with a wide range of antimicrobial agents.
  • Compatibility was assessed after admixture at a specific time point.

Main Results:

  • Imipenem/cilastatin/relebactam demonstrated compatibility with a broad spectrum of antimicrobial agents.
  • Exceptions included amphotericin B deoxycholate and posaconazole.
  • No significant physical incompatibilities were observed with compatible agents.

Conclusions:

  • Y-site administration of imipenem/cilastatin/relebactam with most antimicrobials is feasible.
  • This compatibility facilitates hospital protocol integration and therapy optimization.
  • Co-administration can reduce total infusion time, optimize PK/PD, and contain costs.

Related Concept Videos

Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
6.6K
Acute Pyelonephritis II: Diagnostic Studies and Management01:28

Acute Pyelonephritis II: Diagnostic Studies and Management

Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
207
Antibiotic Selection00:57

Antibiotic Selection

Overview
59.2K
Dosage Interval and Administration Route: Determination Methods01:19

Dosage Interval and Administration Route: Determination Methods

A medication’s effectiveness largely depends on its appropriate dosage and the route of administration. Dosage ensures that a sufficient drug concentration is maintained in the bloodstream to elicit the desired therapeutic effect without causing toxicity. The route of administration affects the drug's bioavailability, rate of absorption, and onset of action, which are crucial for achieving optimal therapeutic outcomes. Drug dosage calculations are critical to tailoring therapy to...
137
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
664
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
130